[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lung-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Lung Squamous Cell Carcinoma",5,4,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05797168","Phase I\u002FIIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:19:01.741747Z","2026-07-05T05:32:16.816051Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07217171","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas",[20],"Phase 1","2026-08-26T02:16:38.053590Z","2026-05-05T02:43:28.073966Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07109726","A Phase 1\u002F2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT\u002FPI3K\u002FPTEN Pathway Alterations",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.897347Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05049837","PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification",[],"2026-08-26T02:19:09.651016Z","2026-05-13T02:55:06.279915Z",{"nct_id":36,"title":37,"phases":38,"status":40,"updated_at":41,"content_modified":42},"NCT07631299","Nebulized AER101 in Pre-op NSCLC",[39],"Early Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:36.513735Z","2026-06-14T18:39:22.248001Z",[],[45,48,52,55],{"state":46,"count":6,"slug":47},"Texas","texas",{"state":49,"count":50,"slug":51},"California",3,"california",{"state":53,"count":50,"slug":54},"Ohio","ohio",{"state":56,"count":50,"slug":57},"Virginia","virginia"]